Avrion Therapeutics is a spin-off from EPFL developing AAV-based precision gene therapies for neurological disorders. Based on 10+ years of research at the Brain Mind Institute, we design cell-type specific gene therapy vectors, and identify novel targets using a proprietary discovery engine.
Products, services, technology
Bicistronic AAV vector tailored to selectively express therapeutic genes in neurons & astrocytes, to maximize efficacy & reduce risks of side effects. Avrion further develops this vector technology with a potent discovery engine to identify innovative therapeutic targets for neurological disorders.
Our bicistronic gene therapy platform allows co-targeting of neurons and astrocytes from a single AAV. The company is working on its second generation cell-type specific vectors to target other glial cells of therapeutic interest. Collaborations around the use of our bicistronic platform are open.